30 Jul 2026
Remote patient monitoring for obesity is worth $780.0 Mn in 2026 and reaches $3850 Mn by 2036 on Fact.MR39s numbers, a 17.3% CAGR and $3070.0 Mn of new demand. The market works because two things line up: connected devices are spreading, and remote monitoring now gets reimbursed. Weight trajectory is the leading monitoring focus at 47.4%, connected scales the leading device type at 35.8%, and CPT RPM codes cover 50.1% of reimbursement. The USA (17.0%), the UK (16.4%), and Australia (16.1%) grow fastest.
Care teams are wiring remote monitoring into obesity and GLP-1 care so weight gets tracked between visits. The priority is a reliable weight signal, which is why connected scales anchor most programs. Reimbursement through CPT RPM codes has made these programs financially sustainable, and endocrinology and obesity-medicine settings are leading the adoption. What clinicians actually specify is dependable data they can act on.
Weight trajectory leads monitoring focus at 47.4%, the core metric in obesity management. Connected scales lead device type at 35.8%, the simplest route to reliable home data. CPT RPM codes cover 50.1% of reimbursement, endocrinology/obesity medicine is 30.3% of care settings, and health systems are the top end user at 46.7%. Reimbursement-anchored, built on weight-focused device data.
The USA leads at 17.0%, then the UK (16.4%), Australia (16.1%), Canada (15.8%), and Germany (15.3%). Growth tracks reimbursement availability and the spread of connected devices. Asia Pacific, including China and India, is represented in the full report39s country-level analysis, though the disclosed leaders sit in North America and Europe where RPM billing is established. The USA moves fastest thanks to its mature reimbursement pathways.
Data quality is the catch. Unreliable home readings undermine the clinical value, so measurement quality is the leading restraint. There is also a volume problem, since too many signals can swamp a care team. Reimbursement conditions add constraints on which programs qualify and scale. The winners ensure data quality and keep workflows manageable.
Withings Health Solutions, Cadence, Vivo Care, Athelas (Commure), and Impilo supply the devices and monitoring services behind obesity care. Several pair connected scales with software that filters raw data into actionable alerts. Reliable measurement and workflows that fit reimbursement rules are where the competition sits, alongside device quality and clinician usability.
Measurement reliability drives the decisions, so watch it. Look at how a vendor filters signals to avoid overwhelming clinicians. Keep reimbursement rules in view, since they decide which programs are viable, and check how monitoring integrates with GLP-1 and broader obesity care. US reimbursement policy sets the pace.
Segmentation covers device type, monitoring focus, reimbursement pathway, care setting, end user, and region, with country-level growth compared across North America, Europe, Asia Pacific, Central and South America, and the Middle East amp Africa from 2026 to 2036. The report supports health systems, care teams, and device providers evaluating remote obesity monitoring, combining segment shares, country CAGRs, and a driver-restraint view.
Expert analysis, actionable insights, and strategic recommendations of the highly seasoned healthcare team at Fact.MR helps clients from across the globe with their unique business intelligence needs. With a repertoire of over a thousand reports and 1 million-plus data points, the team has analyzed the healthcare industry across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Reach out to explore how we can help.
For more information, refer to our market research report or contact the PR author.
Remote Patient Monitoring for Obesity Market
Free SampleAbout Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. We are known for our syndicated research, custom research, and consulting solutions.